<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365532</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-372-1666</org_study_id>
    <nct_id>NCT02365532</nct_id>
  </id_info>
  <brief_title>Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of oral GS-6615 on QTc interval in healthy adults with
      dofetilide-induced QTc prolongation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in daytime QT interval corrected for heart rate using the Fridericia formula (QTcF)</measure>
    <time_frame>Up to 6 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profiles of GS-6615 and dofetilide</measure>
    <time_frame>Predose and postdose on Days -2 through Day 4</time_frame>
    <description>This endpoint will measure the plasma PK profiles of GS-6615 and dofetilide. PK parameters that will be measured include Cmax, Tmax, AUC_0-24, and AUC_0-tlast.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, clinical laboratory test results, vital sign measurements, and electrocardiogram (ECG) data</measure>
    <time_frame>Up to 6 days</time_frame>
    <description>This endpoint will measure the safety and tolerability profile of GS-6615.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Long QT Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo to match GS-6615</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match GS-6615 + dofetilide or placebo to match dofetilide twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-6615</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-6615 or placebo to match GS-6615 + dofetilide or placebo to match dofetilide twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-6615</intervention_name>
    <description>GS-6615 tablets administered orally</description>
    <arm_group_label>GS-6615</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match GS-6615</intervention_name>
    <description>Placebo to match GS-6615 tablets administered orally</description>
    <arm_group_label>Placebo to match GS-6615</arm_group_label>
    <arm_group_label>GS-6615</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match dofetilide</intervention_name>
    <description>Placebo to match dofetilide capsules administered orally</description>
    <arm_group_label>Placebo to match GS-6615</arm_group_label>
    <arm_group_label>GS-6615</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dofetilide</intervention_name>
    <description>Dofetilide 500 Î¼g capsules administered orally according to the current prescribing information</description>
    <arm_group_label>Placebo to match GS-6615</arm_group_label>
    <arm_group_label>GS-6615</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must, in the opinion of the investigator, be in good health based upon medical history
             and physical examination, including vital signs

          -  Have a calculated body mass index (BMI) from 18 to 30 kg/m^2, inclusive, at study
             screening

          -  Have either a normal 12-lead electrocardiogram (ECG) or one with abnormalities that
             are considered clinically insignificant and which do not interfere with the ability to
             interpret the QT interval in the opinion of the investigator in consultation with the
             medical monitor

        Exclusion Criteria:

          -  History of meningitis or encephalitis, epilepsy, seizures (known or suspected),
             migraines, tremors, myoclonic jerks, sleep disorder, anxiety, syncope, head injuries,
             or a family history of seizures

          -  Have any serious or active medical or psychiatric illness (including depression)
             which, in the opinion of the investigator, would interfere with treatment, assessment,
             or compliance with the protocol. This would include renal, cardiac, hematological,
             hepatic, pulmonary (including chronic asthma), endocrine (including diabetes), central
             nervous, gastrointestinal (including an ulcer), vascular, metabolic (thyroid
             disorders, adrenal disease), immunodeficiency disorders, active infection, or
             malignancy that are clinically significant or requiring treatment.

          -  Presence or history of cardiovascular disease, including structural heart disease,
             myocardial infarction (by ECG and/or clinical history), history of ventricular
             tachycardia or torsade de pointes, heart failure or cardiomyopathy (by clinical
             history and/or left ventricular ejection fraction &lt; 40%), presence of cardiac
             conduction abnormalities, a family history of Long QT or Brugada Syndrome, or
             unexplained death in an otherwise healthy individual between the ages of 1 and 30
             years

          -  Additional cardiovascular-specific exclusion criteria include findings on screening
             ECG of:

               -  QTcF interval &gt; 430 msec

               -  PR interval &gt; 220 msec

               -  QRS duration &gt; 110 msec

               -  Second- or third-degree atrioventricular block

               -  Complete left or right bundle branch block or incomplete right bundle branch
                  block

               -  Resting heart rate &lt; 40 or &gt; 100 beats per minute (bpm)

               -  Pathological Q waves (defined as Q wave &gt; 40 msec)

               -  Ventricular pre-excitation

               -  More than 2 ectopic beats

          -  Syncope, palpitations, or unexplained dizziness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly B Patel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spaulding Clinical Research, LLC</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>May 19, 2015</last_update_submitted>
  <last_update_submitted_qc>May 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug-induced long QT syndrome</keyword>
  <keyword>DILQTS</keyword>
  <keyword>prolonged QT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Long QT Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dofetilide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

